Optimal management of asymptomatic carotid stenosis in 2021: the jury is still out. An International, multispecialty, expert review and position statement

Objectives: The recommendations of international guidelines for the management of asymptomatic carotid stenosis (ACS) often vary considerably and extend from a conservative approach with risk factor modification and best medical treatment (BMT) alone, to a more aggressive approach with a carotid intervention plus BMT. The aim of the current multispecialty position statement is to reconcile the conflicting views on the topic. Materials and methods: A literature review was performed with a focus on data from recent studies. Results: Several clinical and imaging high-risk features have been identified that are associated with an increased long-term ipsilateral ischemic stroke risk in patients with ACS. Such high-risk clinical/imaging features include intraplaque hemorrhage, impaired cerebrovascular reserve, carotid plaque echolucency/ulceration/ neovascularization, a lipid-rich necrotic core, a thin or ruptured fibrous cap, silent brain infarction, a contralateral transient ischemic attack/stroke episode, male patients <75 years and microembolic signals on transcranial Doppler. There is growing evidence that 80-99% ACS indicate a higher stroke risk than 50-79% stenoses. Conclusions: Although aggressive risk factor control and BMT should be implemented in all ACS patients, several high-risk features that may increase the risk of a future cerebrovascular event are now documented. Consequently, some guidelines recommend a prophylactic carotid intervention in high-risk patients to prevent future cerebrovascular events. Until the results of the much-anticipated randomized controlled trials emerge, the jury is still out regarding the optimal management of ACS patients

Optimal Management of Asymptomatic Carotid Stenosis in 2021:The Jury is Still Out. An International, Multispecialty, Expert Review and Position Statement

Objectives: The recommendations of international guidelines for the management of asymptomatic carotid stenosis (ACS) often vary considerably and extend from a conservative approach with risk factor modification and best medical treatment (BMT) alone, to a more aggressive approach with a carotid intervention plus BMT. The aim of the current multispecialty position statement is to reconcile the conflicting views on the topic. Materials and methods: A literature review was performed with a focus on data from recent studies. Results: Several clinical and imaging high-risk features have been identified that are associated with an increased long-term ipsilateral ischemic stroke risk in patients with ACS. Such high-risk clinical/imaging features include intraplaque hemorrhage, impaired cerebrovascular reserve, carotid plaque echolucency/ulceration/ neovascularization, a lipid-rich necrotic core, a thin or ruptured fibrous cap, silent brain infarction, a contralateral transient ischemic attack/stroke episode, male patients < 75 years and microembolic signals on transcranial Doppler. There is growing evidence that 80–99% ACS indicate a higher stroke risk than 50–79% stenoses. Conclusions: Although aggressive risk factor control and BMT should be implemented in all ACS patients, several high-risk features that may increase the risk of a future cerebrovascular event are now documented. Consequently, some guidelines recommend a prophylactic carotid intervention in high-risk patients to prevent future cerebrovascular events. Until the results of the much-anticipated randomized controlled trials emerge, the jury is still out regarding the optimal management of ACS patients

A fractal nature for polymerized laminin

Polylaminin (polyLM) is a non-covalent acid-induced nano- and micro-structured polymer of the protein laminin displaying distinguished biological properties. Polylaminin stimulates neuritogenesis beyond the levels achieved by ordinary laminin and has been shown to promote axonal regeneration in animal models of spinal cord injury. Here we used confocal fluorescence microscopy (CFM), scanning electron microscopy (SEM) and atomic force microscopy (AFM) to characterize its three-dimensional structure. Renderization of confocal optical slices of immunostained polyLM revealed the aspect of a loose flocculated meshwork, which was homogeneously stained by the antibody. On the other hand, an ordinary matrix obtained upon adsorption of laminin in neutral pH (LM) was constituted of bulky protein aggregates whose interior was not accessible to the same anti-laminin antibody. SEM and AFM analyses revealed that the seed unit of polyLM was a flat polygon formed in solution whereas the seed structure of LM was highly heterogeneous, intercalating rod-like, spherical and thin spread lamellar deposits. As polyLM was visualized at progressively increasing magnifications, we observed that the morphology of the polymer was alike independently of the magnification used for the observation. A search for the Hausdorff dimension in images of the two matrices showed that polyLM, but not LM, presented fractal dimensions of 1.55, 1.62 and 1.70 after 1, 8 and 12 hours of adsorption, respectively. Data in the present work suggest that the intrinsic fractal nature of polymerized laminin can be the structural basis for the fractal-like organization of basement membranes in the neurogenic niches of the central nervous system.This work was supported by a grant from the Brazilian National Research Council (CNPq; 476772/2008-7) to TCS. MSS acknowledges support from the European Research Council through ERC - 306990. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Hochman Méndez, C.; Cantini ., M.; Moratal Pérez, D.; Salmerón Sánchez, M.; Coelho-Sampaio, T. (2014). A fractal nature for polymerized laminin. PLoS ONE. 9(10):109388-1-109388-11. https://doi.org/10.1371/journal.pone.0109388S109388-1109388-11910Durbeej, M. (2009). Laminins. Cell and Tissue Research, 339(1), 259-268. doi:10.1007/s00441-009-0838-2Miner, J. H., & Yurchenco, P. D. (2004). LAMININ FUNCTIONS IN TISSUE MORPHOGENESIS. Annual Review of Cell and Developmental Biology, 20(1), 255-284. doi:10.1146/annurev.cellbio.20.010403.094555Yurchenco, P. D. (2010). Basement Membranes: Cell Scaffoldings and Signaling Platforms. Cold Spring Harbor Perspectives in Biology, 3(2), a004911-a004911. doi:10.1101/cshperspect.a004911Hohenester, E., & Yurchenco, P. D. (2013). Laminins in basement membrane assembly. Cell Adhesion & Migration, 7(1), 56-63. doi:10.4161/cam.21831Freire, E., & Coelho-Sampaio, T. (2000). Self-assembly of Laminin Induced by Acidic pH. Journal of Biological Chemistry, 275(2), 817-822. doi:10.1074/jbc.275.2.817Freire, E., Sant’Ana Barroso, M. M., Klier, R. N., & Coelho-Sampaio, T. (2011). Biocompatibility and Structural Stability of a Laminin Biopolymer. Macromolecular Bioscience, 12(1), 67-74. doi:10.1002/mabi.201100125Freire, E. (2002). Structure of laminin substrate modulates cellular signaling for neuritogenesis. Journal of Cell Science, 115(24), 4867-4876. doi:10.1242/jcs.00173Hochman-Mendez, C., Lacerda de Menezes, J. R., Sholl-Franco, A., & Coelho-Sampaio, T. (2013). Polylaminin recognition by retinal cells. Journal of Neuroscience Research, 92(1), 24-34. doi:10.1002/jnr.23298Menezes, K., Ricardo Lacerda de Menezes, J., Assis Nascimento, M., de Siqueira Santos, R., & Coelho-Sampaio, T. (2010). Polylaminin, a polymeric form of laminin, promotes regeneration after spinal cord injury. The FASEB Journal, 24(11), 4513-4522. doi:10.1096/fj.10-157628Barroso, M. M. S., Freire, E., Limaverde, G. S. C. S., Rocha, G. M., Batista, E. J. O., Weissmüller, G., … Coelho-Sampaio, T. (2008). Artificial Laminin Polymers Assembled in Acidic pH Mimic Basement Membrane Organization. Journal of Biological Chemistry, 283(17), 11714-11720. doi:10.1074/jbc.m709301200Freire, E. (2004). Sialic acid residues on astrocytes regulate neuritogenesis by controlling the assembly of laminin matrices. Journal of Cell Science, 117(18), 4067-4076. doi:10.1242/jcs.01276Hausdorff, F. (1918). Dimension und �u�eres Ma�. Mathematische Annalen, 79(1-2), 157-179. doi:10.1007/bf01457179Soille, P., & Rivest, J.-F. (1996). On the Validity of Fractal Dimension Measurements in Image Analysis. Journal of Visual Communication and Image Representation, 7(3), 217-229. doi:10.1006/jvci.1996.0020Theiler, J. (1990). Estimating fractal dimension. Journal of the Optical Society of America A, 7(6), 1055. doi:10.1364/josaa.7.001055Otsu, N. (1979). A Threshold Selection Method from Gray-Level Histograms. IEEE Transactions on Systems, Man, and Cybernetics, 9(1), 62-66. doi:10.1109/tsmc.1979.4310076Iranfar, H., Rajabi, O., Salari, R., & Chamani, J. (2012). Probing the Interaction of Human Serum Albumin with Ciprofloxacin in the Presence of Silver Nanoparticles of Three Sizes: Multispectroscopic and ζ Potential Investigation. The Journal of Physical Chemistry B, 116(6), 1951-1964. doi:10.1021/jp210685qPalmero, C. Y., Miranda-Alves, L., Sant’Ana Barroso, M. M., Souza, E. C. L., Machado, D. E., Palumbo-Junior, A., … Nasciutti, L. E. (2013). The follicular thyroid cell line PCCL3 responds differently to laminin and to polylaminin, a polymer of laminin assembled in acidic pH. Molecular and Cellular Endocrinology, 376(1-2), 12-22. doi:10.1016/j.mce.2013.05.020Behrens, D. T., Villone, D., Koch, M., Brunner, G., Sorokin, L., Robenek, H., … Hansen, U. (2012). The Epidermal Basement Membrane Is a Composite of Separate Laminin- or Collagen IV-containing Networks Connected by Aggregated Perlecan, but Not by Nidogens. Journal of Biological Chemistry, 287(22), 18700-18709. doi:10.1074/jbc.m111.336073Colognato, H., Winkelmann, D. A., & Yurchenco, P. D. (1999). Laminin Polymerization Induces a Receptor–Cytoskeleton Network. The Journal of Cell Biology, 145(3), 619-631. doi:10.1083/jcb.145.3.619Liesi, P., & Silver, J. (1988). Is astrocyte laminin involved in axon guidance in the mammalian CNS? Developmental Biology, 130(2), 774-785. doi:10.1016/0012-1606(88)90366-1Zhou, F. C. (1990). Four patterns of laminin-immunoreactive structure in developing rat brain. Developmental Brain Research, 55(2), 191-201. doi:10.1016/0165-3806(90)90200-iGarcia-Abreu, J., Cavalcante, L. A., & Neto, V. M. (1995). Differential patterns of laminin expression in lateral and medial midbrain glia. NeuroReport, 6(5), 761-764. doi:10.1097/00001756-199503270-00014Kazanis, I., & ffrench-Constant, C. (2011). Extracellular matrix and the neural stem cell niche. Developmental Neurobiology, 71(11), 1006-1017. doi:10.1002/dneu.20970Mercier F, Schnack J, Chaumet MSG (2011) Chapter 4 Fractones: home and conductors of the neural stem cell niche. In: Seki, T., Sawamoto, K., Parent, J. M., Alvarez-Buylla, A., (Eds.) Neurogenesis in the adult brain I: neurobiology. Springer. pp 109–133.CAVALCANTIADAM, E., MICOULET, A., BLUMMEL, J., AUERNHEIMER, J., KESSLER, H., & SPATZ, J. (2006). Lateral spacing of integrin ligands influences cell spreading and focal adhesion assembly. European Journal of Cell Biology, 85(3-4), 219-224. doi:10.1016/j.ejcb.2005.09.011Frith, J. E., Mills, R. J., & Cooper-White, J. J. (2012). Lateral spacing of adhesion peptides influences human mesenchymal stem cell behaviour. Journal of Cell Science, 125(2), 317-327. doi:10.1242/jcs.087916Hernández, J. C. R., Salmerón Sánchez, M., Soria, J. M., Gómez Ribelles, J. L., & Monleón Pradas, M. (2007). Substrate Chemistry-Dependent Conformations of Single Laminin Molecules on Polymer Surfaces are Revealed by the Phase Signal of Atomic Force Microscopy. Biophysical Journal, 93(1), 202-207. doi:10.1529/biophysj.106.102491Douet, V., Kerever, A., Arikawa-Hirasawa, E., & Mercier, F. (2013). Fractone-heparan sulphates mediate FGF-2 stimulation of cell proliferation in the adult subventricular zone. Cell Proliferation, 46(2), 137-145. doi:10.1111/cpr.12023Nikolova, G., Strilic, B., & Lammert, E. (2007). The vascular niche and its basement membrane. Trends in Cell Biology, 17(1), 19-25. doi:10.1016/j.tcb.2006.11.005Yurchenco, P. D., Amenta, P. S., & Patton, B. L. (2004). Basement membrane assembly, stability and activities observed through a developmental lens. Matrix Biology, 22(7), 521-538. doi:10.1016/j.matbio.2003.10.006Nikolova, G., Jabs, N., Konstantinova, I., Domogatskaya, A., Tryggvason, K., Sorokin, L., … Lammert, E. (2006). The Vascular Basement Membrane: A Niche for Insulin Gene Expression and β Cell Proliferation. Developmental Cell, 10(3), 397-405. doi:10.1016/j.devcel.2006.01.015Qu, H., Liu, X., Ni, Y., Jiang, Y., Feng, X., Xiao, J., … Zheng, C. (2014). Laminin 411 acts as a potent inducer of umbilical cord mesenchymal stem cell differentiation into insulin-producing cells. Journal of Translational Medicine, 12(1), 135. doi:10.1186/1479-5876-12-135Kanatsu-Shinohara, M., & Shinohara, T. (2013). Spermatogonial Stem Cell Self-Renewal and Development. Annual Review of Cell and Developmental Biology, 29(1), 163-187. doi:10.1146/annurev-cellbio-101512-122353Lander, A. D., Kimble, J., Clevers, H., Fuchs, E., Montarras, D., Buckingham, M., … Oskarsson, T. (2012). What does the concept of the stem cell niche really mean today? BMC Biology, 10(1). doi:10.1186/1741-7007-10-19Loulier, K., Lathia, J. D., Marthiens, V., Relucio, J., Mughal, M. R., Tang, S.-C., … ffrench-Constant, C. (2009). β1 Integrin Maintains Integrity of the Embryonic Neocortical Stem Cell Niche. PLoS Biology, 7(8), e1000176. doi:10.1371/journal.pbio.100017

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND: Disorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021. METHODS: We estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined. FINDINGS: Globally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer. INTERPRETATION: As the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed

Therapeutic blockade of activin-A improves NK cell function and antitumor immunity

Natural killer (NK) cells are innate lymphocytes that play a major role in immunosurveillance against tumor initiation and metastatic spread. The signals and checkpoints that regulate NK cell fitness and function in the tumor microenvironment are not well defined. Transforming growth factor-beta (TGF-beta) is a suppressor of NK cells that inhibits interleukin-15 (IL-15)-dependent signaling events and increases the abundance of receptors that promote tissue residency. Here, we showed that NK cells express the type I activin receptor ALK4, which, upon binding to its ligand activin-A, phosphorylated SMAD2/3 to suppress IL-15-mediated NK cell metabolism. Activin-A impaired human and mouse NK cell proliferation and reduced the production of granzyme B to impair tumor killing. Similar to TGF-beta, activin-A also induced SMAD2/3 phosphorylation and stimulated NK cells to increase their cell surface expression of several markers of ILC1 cells. Activin-A also induced these changes in TGF-beta receptor-deficient NK cells, suggesting that activin-A and TGF-beta stimulate independent pathways that drive SMAD2/3-mediated NK cell suppression. Last, inhibition of activin-A by follistatin substantially slowed orthotopic melanoma growth in mice. These data highlight the relevance of examining TGF-beta-independent SMAD2/3 signaling mechanisms as a therapeutic axis to relieve NK cell suppression and promote antitumor immunity

TCF-1 limits the formation of Tc17 cells via repression of the MAF–RORγt axis

Interleukin (IL)-17–producing CD8 T (Tc17) cells have emerged as key players in host-microbiota interactions, infection, and cancer. The factors that drive their development, in contrast to interferon (IFN)-γ–producing effector CD8 T cells, are not clear. Here we demonstrate that the transcription factor TCF-1 (Tcf7) regulates CD8 T cell fate decisions in double-positive (DP) thymocytes through the sequential suppression of MAF and RORγt, in parallel with TCF-1–driven modulation of chromatin state. Ablation of TCF-1 resulted in enhanced Tc17 cell development and exposed a gene set signature to drive tissue repair and lipid metabolism, which was distinct from other CD8 T cell subsets. IL-17–producing CD8 T cells isolated from healthy humans were also distinct from CD8IL-17− T cells and enriched in pathways driven by MAF and RORγt. Overall, our study reveals how TCF-1 exerts central control of T cell differentiation in the thymus by normally repressing Tc17 differentiation and promoting an effector fate outcome